Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sera from 71 patients with localized lung cancer, from 70 normal controls, and from 73 patients with benign lung diseases were analyzed for 10 substances to detect lung cancer: ferritin, lipid-bound sialic acid, total sialic acid, beta 2-microglobulin, lipotropin, the alpha and beta subunits of human chorionic gonadotropin, calcitonin (two assays), parathyroid hormone, and carcinoembryonic antigen (CEA). Individual markers were studied, and optimal combinations of markers were sought for discriminating patients with localized lung cancer from normal controls and from patients with benign lung disease. Both logistic regression and recursive partitioning methods for discrimination were tried. The best rules involved only CEA and ferritin for discriminating patients with lung cancer from normal controls, and CEA and age for discriminating patients with lung cancer from those with benign lung diseases. The performance of these rules was validated on an independent serum panel containing sera from 56 patients with localized lung cancer, 75 normal controls, and 75 patients with benign lung diseases. Three rules designed to achieve 95% specificity against normal controls attained 14%-36% sensitivity for localized lung cancer in the validation panels, whereas three rules designed to achieve 95% specificity against benign lung diseases attained 30%-39% sensitivity. Some aspects of potential clinical applications are discussed.
 ...
PMID:Multiple markers for lung cancer diagnosis: validation of models for localized lung cancer. 334 91

In 24 hemodialyzed uremic patients the serum levels of iron, ferritin, transferrin and parathyroid hormone were determined and the iron absorption in the gastrointestinal tract after an oral load was studied. Moderately elevated iron levels but extremely high concentrations of ferritin in the blood serum were found. A significant positive correlation was found between serum ferritin and iron levels as well as between serum ferritin and the cumulative volume of transfused blood. No correlation was stated between serum PTH and ferritin levels. No abnormality in iron absorption in the gastrointestinal tract was found. The obtained results suggest the necessity of monitoring ferritin levels as a reliable indicator of whole body iron stores in hemodialyzed uremic patients. Hyperfunction of the parathyroid glands does not seem to play an important role in the pathogenesis of abnormal iron metabolism in hemodialyzed patients.
 ...
PMID:[Iron balance in hemodialysis in chronic uremia]. 340 Mar 53

The effect of continuous ambulatory peritoneal dialysis (CAPD) on anemia was examined in 10 patients over a period of 6 mo. The mean hemoglobin levels in these patients did not change during this period and were not different from those of a group of 10 patients on hemodialysis. There were no changes in serum iron, iron saturation, serum haptoglobin, serum parathyroid hormone and red cell survival during this period. There was an inverse correlation between serum ferritin and hemoglobin levels. These studies show that CAPD is not associated with an improvement in anemia of uremic patients. Previous report on improvement in anemia most likely reflected the smaller loss of blood during CAPD compared with hemodialysis.
 ...
PMID:Effect of continuous ambulatory peritoneal dialysis on anemia in uremic patients. 688 43

The Authors have tested serum levels of CEA, ferritin, Alpha-1-antitrypsin, parathyroid hormone (PTH) and calcitonin (CT) in 286 patients affected by lung, gastrointestinal, breast and other kinds of cancer and by non neoplastic diseases. 50 healthy subjects were tested as matched controls too. None of the tested patients was subjected to blood transfusion, therapy with iron, radio- or chemotherapy before the blood drawing. Cea, ferritin, PTH and CT were tested by radioimmunoassay; AAT by laser nephelometry. All the healthy subjects showed serum levels of the markers in the normal ranges. Also the percent of cases with contemporaneous pathological markers was examined. The obtained data have been statistically controlled with "chi square" test. The results show that CEA, ferritin, AAT and CT are higher in the tumor groups than in the others. On the contrary PTH seems to be not useful as tumor marker. The Authors conclude affirming that it is not possible to use any of the tested substances as a specific tumor marker but it is useful to test at the same time these markers in the patients suspected to be affected by cancer for an early diagnosis and therapy, as there are few false positive and false negative cases.
 ...
PMID:[Association of serum tumor markers in solid neoplasms (CEA, ferritin, alpha 1-antitrypsin, parathormone and calcitonin)]. 698 16

Sera from 254 females were assayed for markers of tumor growth, such as cancer embryonal antigen (CEA), breast cancer-associated antigen (CA 15-3), mucinoid cancer antigen (MCA), ferritin, tissue polypeptide antigen (TPA), parathyroid hormone (PTH) by means of monoclonal antibody kits by using radioimmunoassay and enzyme immunoassay. Forty nine patients were diagnosed as having benign breast neoplasms, 171 patients were admitted to the clinic for primary breast cancer of varying severities, 34 patients without any breast abnormalities and somatic diseases comprised a control group. There was a close correlation between the higher levels of markers and the stage of a tumorous process. Various therapies-induced decreases in the levels of the markers serve as an objective criterion for the efficiency of the latter. Steady increases in the mean concentrations of tumor markers in the intra- and post-therapeutical periods are indicative of an extremely poor prognosis in this group of patients.
 ...
PMID:[Tumor markers CEA, CA 15-3, MCA, TPA, ferritin and PTH in the diagnosis and monitoring of primary breast cancer]. 778 Mar 32

Erythropoietin (EPO) given subcutaneously (SC) once per week has been successful in the treatment of anemia in continuous ambulatory peritoneal dialysis (CAPD) patients. We have identified a population of CAPD patients that requires EPO administration once per week or less often. To determine if specific variables could be identified that would predict which CAPD patients would require infrequent EPO dosing, we reviewed the charts of all our CAPD patients who were receiving EPO as of 1 June 1992. Patients had to have been on CAPD for 3 months and EPO for 3 months to be considered for analysis. We identified 12 patients who required EPO once per week or less frequently (infrequent EPO) and 9 patients who required EPO more than once per week (frequent EPO). Parameters that were analyzed included age, gender, race, time on CAPD, history of gastrointestinal bleeding, exit-site infection or peritonitis in the last 60 days, diabetes, amount of dialysate instilled per day, and the number of exchanges per day. Laboratory data that were analyzed included hemoglobin, hematocrit, serum iron, total iron-binding capacity, ferritin, blood urea nitrogen (BUN), creatinine, BUN/creatinine ratio, albumin, total protein, parathyroid hormone, and aluminum. Categorical data were analyzed via chi-square, and numerical data were analyzed via the t-test. The infrequent EPO group required only 35% as much EPO as the frequent group to maintain hemoglobin and hematocrit, which were significantly greater. The only parameter that was different between the two groups was age (infrequent EPO 42 +/- 13.2 vs frequent EPO 55.8 +/- 11.9 years, p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD. 810 57

To evaluate the effects of erythropoietin (EPO) therapy on the lipid profile in end-stage renal failure, we undertook a prospective study in patients on both hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). One hundred and twelve patients (81 HD, 31 CAPD) were enrolled into the study. Lipid parameters [that is, total cholesterol and the LDL and HDL subfractions, triglycerides, lipoprotein (a), apoproteins A and B], full blood count, iron studies, B12, folate, blood urea, aluminium and serum parathyroid hormone were measured prior to commencement of EPO therapy. Ninety-five patients were reassessed 5.2 +/- 0.3 (mean +/- SEM) months later and 53 patients underwent a further assessment 13.1 +/- 0.6 months after the commencement of EPO, giving an overall follow-up of 10.0 +/- 0.6 months in 95 patients. As expected, EPO treatment was associated with an increase in hemoglobin (7.7 +/- 0.1 vs. 9.9 +/- 0.2 g/dl; P < 0.001) and a decrease in ferritin (687 +/- 99 vs. 399 +/- 69 micrograms/liter; P < 0.01). A significant fall in total cholesterol occurred (5.8 +/- 0.1 vs. 5.4 +/- 0.2 mmol/liter; P < 0.05) in association with a fall in apoprotein B (1.15 +/- 0.04 vs. 1.04 +/- 0.06; P < 0.05) and serum triglycerides (2.26 +/- 0.14 vs. 1.99 +/- 0.21; P < 0.05) during the course of the study. Other lipid parameters did not change, although there was a trend towards improvement.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. 819 94

Recombinant human erythropoietin (rHuEpo) seems to be more efficient when given subcutaneously (SC) instead of intravenously (IV) for therapy of anaemia in haemodialysis patients. This was a cross-over study designed to assess the efficiency of rHuEpo when given SC rather than IV in a 1 year follow-up. Sixteen patients received IV rHuEpo for 6 months, then SC rHuEpo for 6 months. They were four males and 12 females with a mean age of 56 years (range 15-82). Haemoglobin concentration ([Hb]) was kept at 10 g/dl and transferrin saturation (TS) at more than 25%. Mean [Hb] was 9.7 +/- 1.0 g/dl with IV rHuEpo and 9.9 +/- 0.9 g/dl with SC rHuEpo (NS). Transferrin saturation was 27% before rHuEpo, 31% with IV rHuEpo and 34% with SC rHuEpo (NS vs IV rHuEpo). Serum ferritin was 691 +/- 113 ng/ml before rHuEpo, 652 +/- 94 ng/ml with IV rHuEpo and 997 +/- 132 ng/ml with SC rHuEpo (P < 0.05 vs IV rHuEpo). Intact parathyroid hormone was 354 +/- 83 pg/ml before rHuEpo, 201 +/- 63 pg/ml with IV rHuEpo and 122 +/- 33 pg/ml with SC rHuEpo (NS vs IV rHuEpo). Doses of IV rHuEpo were 156 +/- 24 U/kg/week and SC rHuEpo 74 +/- 13 U/kg/week (i.e. a saving of 53%; P < 0.001). We conclude that subcutaneous administration of rHuEpo is twice as efficient as IV rHuEpo in patients with good functional iron reserve.
 ...
PMID:Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. 852 93

There is increased incidence of infectious complications in uremic patients, indicating impairment of cellular host defense in these patients. Several reports confirm metabolic and functional abnormalities of polymorphonuclear leukocytes (PMNL) including altered adherence to endothelial cells, altered generation of reactive oxygen species, altered release of microbial enzymes, impaired chemotaxis, phagocytosis, intracellular killing of bacteria, altered carbohydrate metabolism, and/or impaired ATP formation. Several studies report on correlations between PMNL dysfunction, especially phagocytosis and oxidative burst, and ferritin content. Deferoxamine therapy improved PMNL function. Chronic renal failure is a state of increased cytosolic calcium. Increased cytosolic calcium is associated with several alterations of PMNL function and metabolism, which improve by normalization of cytosolic calcium either by calcium channel blockers or by lowering of elevated parathyroid hormone. Each hemodialysis session using bioincompatible membranes triggers neutrophil activation, evidenced by overexpression of adhesion molecules, elevation of cytosolic calcium, release of PMNL granular enzymes, and generation of reactive oxygen species. Several studies claim that this results in chronic downregulation of phagocyte function. Several granulocyte inhibitory compounds have been isolated and characterized from uremic serum. The uremic retention product p-cresol depresses respiratory burst activity. The following granulocyte inhibitory peptides could be isolated from dialysis patients: granulocyte inhibitory protein I and II with homology to light chain proteins and beta 2-microglobulin, degranulation inhibitory protein I and II being identical to angiogenin and complement factor D, and immunoglobulin light chains. These proteins inhibit PMNL function in nanomolar concentrations.
 ...
PMID:Dysfunction of polymorphonuclear leukocytes in uremia. 873 62

Forty patients with chronic renal failure (CRF) were enrolled into the study, none of whom had peptic ulcer disease, amyloidosis, a previous abdominal operation, diabetes mellitus or other factors that could influence gastric emptying. Twenty of the 40 patients had been receiving regular haemodialysis (HD) for at least 1 year prior to the study. Twelve of the 40 patients had upper gastrointestinal symptoms/signs (GI Sx). Radionuclide-labelled solid meals were used to calculate gastric emptying time (GET). Twenty-five normal volunteers comprised the control group. Of the 40 patients, 35 (88%) had an abnormal GET. The incidence of an abnormal GET in HD and non-HD patients was 95 and 80%, respectively; the incidence of an abnormal GET in patients with and without upper GI Sx was 83 and 89%, respectively. These differences in the incidence of an abnormal GET among the HD and non-HD patients, as well as in the patients with and without upper GI Sx, were not statistically significant. There were no significant differences between the normal and abnormal GET patients for any of the following clinical parameters and conditions: dialyser-specific proportionality constant x time/urea distribution volume (KT/V), protein catabolic rate (PCR), ferritin, serum blood urea nitrogen, creatinine, calcium ion, phosphate, intact parathyroid hormone, albumin, uric acid, haemoglobin, triglyceride and cholesterol, total dialysis time, creatinine clearance and daily urine protein. We conclude that in Chinese patients with CRF, both dialysed and undialysed, an abnormal GET is common. The pathogenesis seems to be multifactorial. The presence of abdominal symptoms cannot foretell an abnormal GET.
 ...
PMID:Delayed gastric emptying in patients with chronic renal failure. 877 42


<< Previous 1 2 3 4 5 6 7 8 9 Next >>